After canceling meeting of independent advisers, FDA issues 2025-26 flu vaccine recommendations
The FDA's Vaccines and Related Biological Products Advisory Committee had been scheduled to meet Thursday to weigh in on the composition of the flu shots, but that session was canceled without explanation in late February.
Instead, experts from within the FDA, the US Centers for Disease Control and Prevention and the US Department of Defense gathered Thursday to go over surveillance data from the US and around the world about flu viruses that are currently circulating.
The FDA is recommending that flu vaccines for the 2025-26 season be trivalent, protecting against two strains of influenza A and one of influenza B.
'The FDA anticipates that there will be an adequate and diverse supply of approved trivalent seasonal influenza vaccines' for the upcoming virus season, it said in a statement.
There are several ways to make flu vaccines, but the most common is to grow the selected candidate viruses in chicken eggs, a painstaking operation that takes months to finish.
For that reason, selection of the strains that will be included in flu vaccines is carefully orchestrated to be sure manufacturers can deliver the shots to doctors' offices and pharmacies in time.
In order for flu vaccines to be sold in the US, they must contain strains that are officially selected by the FDA.
That decision typically comes after a meeting of the World Health Organization's Global Influenza Surveillance and Response System, a network of seven collaborating centers and four essential regulatory labs, which are based in the US, UK, Japan, China, Russia and Australia. Both the CDC and the FDA are members.
These experts meet twice a year — in the fall and spring — to choose strains for countries in the Southern and Northern Hemispheres. WHO's own vaccine recommendations for 2025-26 generally parallel those of the FDA.
Typically, the 17-member FDA vaccine committee would meet next and publicly discuss the recommendation and make its own endorsement, and then the agency would make its final decision.
The cancellation of the committee meeting had prompted concerns about the timing of and access to flu shots for this fall. 'I'm glad that they've come out with the influenza recommendation in a timely manner,' Dr. Paul Offit, a member of the independent advisory committee and director of the Vaccine Education Center at the Philadelphia Children's Hospital, said Thursday.
The 2024-25 flu season – the worst in the US in more than a decade – is believed to have peaked in early February. The CDC estimated in early March that there had been at least 40 million illnesses, 520,000 hospitalizations and 22,000 deaths caused by flu this season.
CNN's Meg Tirrell contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer
Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food and Drug Administration (FDA) to treat breast cancer. The treatment is aimed at patients with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), oestrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer who have previously undergone endocrine-based therapy. The Prescription Drug User Fee Act (PDUFA) action date is set for 5 June 2026. Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication designed to degrade oestrogen receptors. It is being developed collaboratively by Arvinas and Pfizer as a potential monotherapy option. The submission was based on results from VERITAC-2, a randomised, global Phase III study that compared vepdegestrant against fulvestrant. Patients were randomly assigned in a 1:1 ratio to receive either vepdegestrant, administered orally once daily on a continuous 28-day schedule, or fulvestrant, which was given intramuscularly. 43% of the patients in the trial had detectable ESR1 mutations. Progression-free survival (PFS), measured both in patients with ESR1 mutations and across all trial participants, served as the primary endpoint evaluated through blinded independent central review. Overall survival (OS) remains an important secondary endpoint. Arvinas chairperson, CEO and president John Houston stated: 'Patients often face limited treatment options after first-line treatment and vepdegestrant demonstrated improved progression-free survival in patients with ESR1-mutated ER+/HER2- advanced breast cancer. 'With the efficacy and favourable tolerability seen in VERITAC-2, we believe vepdegestrant, if approved, has potential to be a best-in-class treatment option for patients in the second-line ESR1-mutant setting.' In August 2025, Pfizer raised its full-year profit forecast, driven by robust sales of its heart disease medication Vyndaqel (tafamidis) and the blood thinner Eliquis (apixaban), among other products. "FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 hours ago
- Yahoo
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
-- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea. The drugmaker's shares climbed 1% in London on the news. The company is looking to new infectious disease products, including its recently launched respiratory syncytial virus vaccine, to offset expected revenue declines from top-selling medicines and looming patent expirations in its HIV portfolio. Gepotidacin is already approved in the U.S. under the brand name Blujepa for treating a common urinary tract infection in women and adolescent girls. The FDA is expected to decide in December on its use for uncomplicated urogenital gonorrhoea, which could offer patients an oral alternative to existing injectable treatments. Separately, GSK and Germany's CureVac last week resolved a long-running patent dispute with Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) over mRNA vaccine technology used during the COVID-19 pandemic. The settlement follows BioNTech's June agreement to acquire CureVac in an all-stock deal worth $1.25 billion to advance work on mRNA-based cancer therapies. Under the settlement, CureVac and GSK will receive $740 million and single-digit percentage royalties on future U.S. sales of COVID-19 vaccines, CureVac said. GSK's share amounts to $370 million, including $50 million to adjust terms from a 2024 licence agreement that expanded their pandemic-era partnership. If BioNTech's takeover of CureVac is completed, related mRNA litigation outside the U.S. will also be resolved, with GSK receiving an additional $130 million and royalties extended to non-U.S. sales. CureVac said the acquisition remains on track under the agreed terms. GSK said it still has separate patent cases against Pfizer and BioNTech in the U.S. and Europe, which are unaffected by this settlement. Related articles GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic USPS blocks major vape distributor over unregulated product shipments - Reuters Exclusive: Opendoor CEO Wheeler breaks silence, EMJ's Eric Jackson calls for more Sign in to access your portfolio
UPI
4 hours ago
- UPI
CDC union calls on Trump officials to condemn vaccine misinformation
The U.S. Centers for Disease Control and Prevention headquarters in Atlanta, Ga. Union representing thousands of CDC workers is calling on the Trump administration to condemn vaccine misinformation after a shooting targeting the headquarters on Friday. File Photo by Erik S. Lesser/EPA-EFE Aug. 11 (UPI) -- The union representing thousands of workers at the U.S. Centers for Disease Control and Prevention is calling on the Trump administration to condemn vaccine disinformation after a gunman killed a police officer in a shooting targeting the CDC headquarters in Georgia. The suspected gunman behind the Friday shooting was identified Saturday as 30-year-old Patrick Joseph White. He was shot dead by police after opening fire at an Emory Point CVS, with police suspecting he targeted the nearby CDC headquarters over health problems he blamed on the COVID-19 vaccine. The American Federation of Government Employees Local 2883, which represents more than 2,000 CDC workers, said in a statement Sunday that the attack "was not random and it compounds months of mistreatment, neglect and vilification that CDC staff have endured." "The deliberate targeting of CDC through this violent act is deeply disturbing, completely unacceptable and an attack on every public servant," the union said. "Early reports indicate the gunman was motivated by vaccine disinformation, which continues to pose a dangerous threat to public health and safety." To its members, it said it is advocating for "a clear and unequivocal stance in condemning disinformation" by the CDC and the leadership of Health and Human Services, which is run by vaccine skeptic Robert F. Kennedy Jr. "This leadership is critical in reinforcing public trust and ensuring that accurate, science-based information prevails," the union said. "This condemnation is necessary to help prevent violence against scientists that may be incited by such disinformation." The shooting occurred just days after Kennedy announced that HHS was moving to terminate $500 million in contracts to develop vaccines using mRNA technology, which was used to develop the COVID-19 vaccine. COVID-19 vaccines are estimated to have saved more than 2 million lives worldwide. The American Medical Association supports mRNA vaccine research. Despite the support from the medical community, Kennedy claimed "the technology poses more risks than benefits." "HHS supports safe, effective vaccines for every American who wants them, that's why we're moving beyond the limitations of mRNA for respiratory viruses," he said. The AMA, in response, urged the Trump administration to reverse course, and to continue "vital research to improve mRNA vaccines, not throw the baby out with the bathwater by effectively preventing research from moving forward." The union said the shooting had CDC employees, including more than 90 children, trapped in buildings throughout the CDC campus late into Friday. It said in its Sunday statement that staff should not be required to return to work until the facility is repaired. The CDC campus was reportedly damaged by bullet holes and shattered windows. "Staff should not be required to work next to bullet holes," it said. "Forcing a return under these conditions risks re-traumatizing staff by exposing them to the reminders of the horrific shooting they endured."
